Comparative Pharmacology
Head-to-head clinical analysis: ALINIA versus PROTOSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALINIA versus PROTOSTAT.
ALINIA vs PROTOSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitazoxanide is a thiazolide antiparasitic agent that inhibits the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction, which is essential for anaerobic energy metabolism in parasites.
Proto-oncogene tyrosine-protein kinase Src inhibitor; inhibits cell proliferation and induces apoptosis in cancer cells overexpressing Src.
500 mg orally twice daily for 3 days, with food.
250 mg orally three times daily after meals for 7-10 days; alternatively, 500 mg twice daily for 7 days.
None Documented
None Documented
Terminal half-life of tizoxanide is approximately 1.5-2 hours in patients with normal renal function; clinical context: short half-life requires twice-daily dosing.
8 hours (range 6-10 h); in renal impairment, half-life prolonged up to 20 hours; dose adjustment required for CrCl < 30 mL/min.
Fecal (75-85% as tizoxanide), renal (5-10% as tizoxanide and conjugates), biliary (minor).
Renal: 70% as unchanged drug; biliary/fecal: 15% as metabolites; 15% other.
Category C
Category C
Antiprotozoal Agent
Antiprotozoal Agent